首页> 外文OA文献 >Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

【2h】

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

机译：氮杂胞苷维持治疗用于高危骨髓增生异常综合征（MDS）或MDS后急性骨髓性白血病的患者，诱导化疗后完全缓解

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

International audience

机译：国际观众

著录项

作者
Grövdal, Michael; Karimi, Mohsen; Khan, Rasheed; Aggerholm, Anni; Antunovic, Petar; Astermark, J; Bernell, Per; Engström, Lena-Maria; Kjeldsen, Lars; Linder, Olle; Nilsson, Lars; Olsson, Anna; Holm, Mette Skov; Tangen, Jon Magnus; Wallvik, Jonas; Öberg, Gunnar; Hokland, Peter; Jacobsen, Sten Eirik; Porwit, Anna; Hellström-Lindberg, Eva;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. [J] . Grovdal M, Karimi M, Khan R, British Journal of Haematology . 2010,第3期

机译：氮杂胞苷维持治疗用于高危骨髓增生异常综合症（MDS）或MDS后急性骨髓性白血病的患者，诱导化疗后完全缓解。
2. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy [J] . Michael Grövdal, Mohsen Karimi, Rasheed Khan, British Journal of Haematology . 2010,第3期

机译：氮杂胞苷维持治疗用于高危骨髓增生异常综合征（MDS）或MDS后急性髓细胞性白血病的患者，诱导化疗后完全缓解
3. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group [J] . Papageorgiou Sotirios G., Kontos Christos K., Kotsianidis Ioannis, Journal of geriatric oncology . 2020,第1期

机译：高氮杂胞苷对老年高风疹脓毒症综合征和低聚细胞急性髓性白血病的有效性：Hellenic（希腊语）MDS研究组的回顾性分析
4. Design of optimal disease and patient-specific chemotherapy protocols for the treatment of Acute Myeloid Leukaemia (AML) [C] . E. Pefani, N. Panoskaltsis, A. Mantalaris International Symposium on Process Systems Engineering . 2012

机译：用于治疗急性髓性白血病（AML）的最佳疾病和患者特异性化疗方案的设计
5. CD16xCD33 bispecific killer cell engager (BiKE) activates natural killer (NK) cells from myelodysplastic syndrome (MDS) patients against primary MDS and myeloidderived suppressor cell (MDSC) CD33-positive targets. [D] . Gleason, Michelle K. 2014

机译：CD16xCD33双特异性杀伤细胞接合剂（BiKE）激活来自骨髓增生异常综合征（MDS）患者的自然杀伤（NK）细胞，以抵抗原发性MDS和髓样抑制细胞（MDSC）CD33阳性靶标。
6. Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial [O] . Dominik Selleslag, Stefan Suciu, Giovanna Meloni, 2017

机译：低剂量氯法拉滨联合标准缓解诱导治疗以前未接受过治疗的中度和重度急性髓性白血病或高危骨髓增生异常综合征的18-60岁患者：EORTC / GIMEMA AML-14A的I / II期综合结果试用
7. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy [O] . Grovdal, Michael, Karimi, Mohsen, Khan, Rasheed, 2010

机译：对于高风险骨髓增生异常综合征（mDs）或mDs后急性髓细胞白血病患者诱导化疗后完全缓解的氮杂胞苷维持治疗

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅